Group 1 - The A-share market experienced a significant increase in public fund research activities in October 2025, with 159 public institutions participating and covering 632 stocks, resulting in a total of 7,452 research instances, a 60.57% increase from September [1] - The computer industry saw a notable focus, with Nengke Technology being the most researched company, receiving 73 research instances from 53 public institutions, highlighting interest in its AI business developments [1] - The top ten researched stocks in October were primarily from the power equipment, machinery, and communication sectors, indicating strong interest in these industries [1][2] Group 2 - The pharmaceutical and biological industry emerged as the hottest sector for research, with 85 stocks receiving a total of 1,229 research instances, significantly outpacing other industries [2][3] - The electronics industry followed closely, with 78 stocks and a total of 1,069 research instances, indicating a strong interest from public institutions [3] - The power equipment and machinery sectors also showed high research activity, each with over 750 research instances and more than 55 stocks being researched [3] Group 3 - Chuangjin Hexin Fund was the most active public institution in October, conducting 302 research instances, primarily focusing on the pharmaceutical, electronics, and machinery sectors [3] - Ping An Fund followed with 169 research instances, concentrating on electronics, machinery, power equipment, and computer industries [3] - Bosera Fund ranked third with 137 research instances, focusing on power equipment and electronics, aligning with current market trends [3]

Core Points - The stock price of United Imaging Healthcare has declined by 6.05% over the last three days, closing at 137.69 CNY per share with a market capitalization of 1134.78 billion CNY [1] - The company specializes in high-performance medical imaging equipment, radiation therapy products, life science instruments, and medical digitalization solutions, with 81.29% of its revenue coming from medical imaging and radiation therapy equipment sales [1] Group 1 - United Imaging Healthcare's stock has seen a trading volume of 9.28 billion CNY and a turnover rate of 0.82% [1] - The company was founded on March 21, 2011, and went public on August 22, 2022 [1] - The revenue breakdown includes 13.56% from maintenance services and 4.68% from other sources, with software revenue contributing 0.47% [1] Group 2 - The fund "Jiaoyin Stable Progress Mixed A" holds 2500 shares of United Imaging Healthcare, representing 0.48% of the fund's net value, ranking it as the seventh largest holding [2] - The fund has experienced a floating loss of approximately 5575 CNY today and a total floating loss of 22,200 CNY during the three-day decline [2] - The fund was established on June 21, 2023, with a current size of 57.26 million CNY and has returned 3.3% year-to-date [2]

Core Insights - Philips Medical has made significant management changes in the Chinese market, appointing Mai Haiyan as the new sales general manager for the imaging division, indicating a strategic shift towards local operational efficiency and market responsiveness [2][4] - The appointment of Mai Haiyan, who has extensive experience across various sectors, reflects a transition from a brand-centric approach to one focused on organizational efficiency and market density [4][7] - The imaging market in China is evolving from a brand-driven era to one characterized by efficiency and service capabilities, with a focus on operational speed and customer engagement [7][9] Group 1: Management Changes - Mai Haiyan's background includes leadership roles in GE Healthcare and domestic companies, showcasing a blend of international and local market experience [4] - The shift in leadership is seen as a response to the changing dynamics of the imaging equipment industry, emphasizing the need for a more agile and responsive organizational structure [2][4] Group 2: Market Dynamics - The Chinese imaging market is transitioning from reliance on brand trust to a focus on service capabilities such as AI assistance and remote operations, which are becoming key competitive advantages [7] - The normalization of centralized procurement is shifting the focus from absolute performance to cost-effectiveness and total ownership costs, impacting market strategies [9] - The market is becoming more fragmented and dense, driven by the simultaneous replacement of equipment in base hospitals and the construction of regional medical centers [9]

Core Viewpoint - The company Shukun Technology is preparing for an IPO, with indications that the current market conditions present a favorable window for this move, as the company aims to capitalize on the improving capital market environment and its own operational progress [1][2][3]. Company Overview - Shukun Technology, established in 2017, is a leading player in the AI medical imaging sector, having achieved a valuation of 9.4 billion yuan after its D-round financing in 2021 [1][2]. - The company has obtained 19 Class III medical device registration certificates, the highest in the industry [1]. Financial Performance and Market Position - Shukun Technology is reportedly on track to achieve profitability by 2025, with current revenue levels deemed sufficient to meet the requirements for a Hong Kong stock market listing [1][2]. - The company has shifted its focus to the grassroots market and international expansion, with several AI products already certified by the FDA and CE, and in use in over 5,000 medical institutions globally [6][10]. Industry Context - The AI medical imaging sector has experienced significant fluctuations, with a previous wave of enthusiasm leading to failed IPO attempts by several leading companies in 2021, leaving only one successful listing [1][2][9]. - The industry is characterized by a common critique of its single-channel entry and unclear profit models, but there are signs of differentiation among companies, with some successfully navigating the challenges [2][11]. Market Sentiment and Future Outlook - The current capital market environment is seen as the best in recent years, with a notable increase in the number of biopharmaceutical and medical device companies listing on the Hong Kong Stock Exchange [2][6]. - Shukun Technology's potential IPO is viewed as a bellwether for the AI medical imaging sector, reflecting broader market sentiments regarding the commercial viability of AI applications in healthcare [2][10]. Challenges and Considerations - Despite the positive outlook, challenges remain regarding the commercial viability of AI medical imaging, particularly in terms of payment mechanisms and integration into clinical workflows [10][12]. - The company’s success in the IPO process will not only impact its future but also set a precedent for other players in the AI medical imaging space [12].

Core Viewpoint - The stock of United Imaging Healthcare has experienced fluctuations, with a recent decline of 2.05% and a total market capitalization of 1129.51 billion yuan, reflecting mixed investor sentiment and market activity [1] Financial Performance - For the period from January to September 2025, United Imaging Healthcare reported a revenue of 88.59 billion yuan, marking a year-on-year increase of 27.39% [2] - The net profit attributable to shareholders for the same period was 11.20 billion yuan, showing a significant year-on-year growth of 66.91% [2] Stock and Market Activity - As of November 3, the stock price was 137.05 yuan per share, with a trading volume of 4.05 billion yuan and a turnover rate of 0.35% [1] - The stock has increased by 8.61% year-to-date, but has seen a decline of 4.71% over the last five trading days and 4.95% over the last twenty days [1] Shareholder and Institutional Holdings - As of September 30, the number of shareholders increased to 32,400, a rise of 96.28%, while the average number of circulating shares per person decreased by 29.23% to 25,444 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 19.04 million shares, a decrease of 2.98 million shares from the previous period [3]

Summary of Key Points Core Viewpoint - In the past five trading days, a total of 487 companies were investigated by institutions, with notable interest in companies such as United Imaging Healthcare, Zhaoyi Innovation, and Jinpan Technology, indicating a trend of concentrated institutional research activity in specific sectors [1]. Institutional Research Activity - 95.69% of the companies investigated had participation from securities firms, with 466 companies being researched by them. Fund companies followed with 411 companies, and private equity firms investigated 321 companies [1]. - Among the companies, 295 received attention from more than 20 institutions, with United Imaging Healthcare being the most researched at 318 institutions, followed by Zhaoyi Innovation at 276 institutions, and Jinpan Technology at 254 institutions [1]. Fund Flow and Stock Performance - Out of the stocks with over 20 institutions researching them, 82 saw net inflows in the past five days. Tianji Co., Ltd. had the highest net inflow of 1.512 billion yuan, followed by Tianqi Materials and Oulu Tong with net inflows of 1.130 billion yuan and 358 million yuan, respectively [1]. - In terms of stock performance, 171 of the researched stocks increased in value, with the highest gains seen in Ruierte (46.59%), Tianji Co., Ltd. (41.86%), and Chutian Technology (24.86%). Conversely, 123 stocks experienced declines, with the largest drops in Kehua Data (-17.30%), Huitai Medical (-14.81%), and Kaili Medical (-14.48%) [2].

Summary of China Medtech Q325 Conference Call Industry Overview - **Industry**: China Medtech - **Key Findings**: The Q325 results of 109 A-share medtech companies showed a median revenue decline of 0.5% YoY, an improvement from -0.7% in Q225. The equipment segment outperformed, with a revenue growth of 10.4% YoY, while IVD (In Vitro Diagnostics) continued to decline at -13.1% YoY [2][4][10]. Core Insights - **Revenue Performance**: - Overall revenue for Q325 was largely flat YoY, with equipment showing robust growth [2]. - Equipment revenue growth was attributed to tender recovery, while IVD revenue decline was linked to panel test unbundling and reagent price cuts [2][3]. - Consumables revenue growth was minimal at 0.1% YoY, with significant variance across companies [2]. - **Profitability Metrics**: - Net profit (NP) to parent remained flat at 0.3% YoY in Q325, a recovery from -10.5% in Q225 [2]. - Equipment segment NP growth was notable at 33.7% YoY, likely due to a low base effect [2]. - NP for IVD and consumables companies decreased by 20.9% and 14.6% YoY, respectively [2]. - **Gross Profit Margin (GPM)**: - GPM for IVD and equipment segments dropped by 3.1 percentage points and 1.3 percentage points, respectively, primarily due to price-related initiatives [2][11]. Domestic Market Dynamics - **VBP (Volume-Based Procurement)**: - Recent proposals by China's NHSA aimed at reducing intense price competition in VBPs, with outcomes still uncertain [3]. - Key catalysts include the results of large-scale VBPs, such as Round 6 national consumables VBP [3]. - **Hospital Equipment Procurement**: - Although tender growth YoY slowed in Q325, equipment companies are expected to see meaningful revenue growth due to recent tender improvements [3]. Overseas Market Challenges - **Geopolitical Risks**: - Ongoing geopolitical tensions are anticipated to impact overseas potential for domestic firms, despite limited current effects [4]. - The US has announced a 100% additional tariff on Chinese imports effective November 1, 2025, and a Section 232 Investigation for medtech is underway [4]. - EU market access restrictions are in place, but the impact has been limited as hospitals may adopt single-source procurement to bypass these restrictions [4]. Investment Recommendations - **Top Picks**: - **United Imaging**: Expected robust revenue growth driven by new product launches and import substitution benefits [5]. - **New Industries**: Anticipated acceleration in revenue and NP growth due to domestic recovery and overseas expansion [5]. - **Weigao**: Projected revenue growth acceleration in H225, with potential synergies from transactions with its parent company [5]. Valuation Metrics - **Market Valuation**: The median PE/PEG for the medtech coverage is 25.0x/1.5x for 2026E [5][7]. - **Company Valuations**: - United Imaging: PE of 49.7x, expected revenue growth of 22.5% [7]. - New Industries: PE of 24.0x, expected revenue growth of 11.7% [7]. - Weigao: PE of 9.9x, expected revenue growth of 6.8% [7]. Risks and Considerations - **Key Risks**: - Price reductions and market share gains from VBP programs may be larger than expected [20][22]. - Weaker-than-expected demand from equipment renewal programs [20][22]. - Geopolitical risks affecting supply chains [20][22]. - Slower-than-expected product R&D and technological breakthroughs [20][22]. Conclusion The China Medtech industry is experiencing a mixed performance with equipment segments showing resilience while IVD continues to face challenges. Geopolitical tensions and domestic procurement policies will be critical factors influencing future growth. Investors are advised to focus on companies with strong growth potential and to remain cautious of the outlined risks.

Company Developments - Ansys China issued a notice to clients stating that the claims made by Nexperia Netherlands regarding the local management's failure to comply with contract payment terms are completely unfounded and maliciously defame Ansys China's management. Ansys China asserts that it has not defaulted on any obligations; rather, Nexperia Netherlands currently owes ATGD a total of 1 billion RMB [2] - BYD reported that its new energy vehicle sales reached 3,701,852 units in the first ten months, marking a year-on-year increase of 13.88%. In October, the total installed capacity of new energy vehicle power batteries and energy storage batteries was approximately 27.362 GWh, with a cumulative total of about 230.613 GWh [6] - Seres announced that its new energy vehicle sales in October were 51,456 units, reflecting a year-on-year increase of 42.89%. The cumulative sales for the year reached 356,085 units, showing a year-on-year growth of 0.95% [6] - Betta Pharmaceuticals has reached a strategic cooperation agreement with Shengsi Bio, acquiring exclusive general agency rights for a recombinant coagulation factor product [6] - OpenAI has officially lifted the invitation code restrictions for its AI video generation tool Sora 2, making it available for download to users in the United States, Canada, Japan, and South Korea. Users can now access it directly through the Apple App Store and log in using their ChatGPT accounts [6] Industry Insights - The China Securities Association reported that as of October 31, a total of 5,446 listed companies in China's domestic stock market disclosed their Q3 2025 reports. The data shows that in the first three quarters, these companies achieved a total operating income of 53.46 trillion RMB and a net profit of 4.70 trillion RMB, representing year-on-year growth of 1.36% and 5.50%, respectively [4] - The A-share market has maintained a strong performance since October, with foreign institutional research remaining active. Companies such as Huaming Equipment, United Imaging Healthcare, Lens Technology, and others have garnered high attention from foreign investors, particularly in high-growth sectors like AI, robotics, and high-end manufacturing [4][5] - The overall trend for November is expected to remain upward, with brokerages favoring sectors such as technology and energy resources. The focus is on low-valuation sectors with profit recovery expectations, while technology growth remains a key area for investment [5]

Core Insights - The stock price of United Imaging Healthcare (688271) closed at 139.92 CNY on October 31, 2025, down 1.58% from the previous week, with a market cap of 115.316 billion CNY [1] Shareholder Changes - As of September 30, 2025, the number of shareholders reached 32,400, an increase of 96.28% compared to June 30, 2025 [1][3] - The average number of shares held per shareholder decreased from 49,900 to 25,400, with an average holding value of 3.86 million CNY [1] Financial Performance - For the first three quarters of 2025, the main revenue was 8.859 billion CNY, a year-on-year increase of 27.39% [1] - The net profit attributable to shareholders was 1.12 billion CNY, up 66.91% year-on-year, while the net profit excluding non-recurring items was 1.053 billion CNY, an increase of 126.94% [1] - In Q3 2025, the single-quarter main revenue was 2.843 billion CNY, a year-on-year increase of 75.41% [1] - The net profit attributable to shareholders for Q3 was 122 million CNY, up 143.8% year-on-year, with a net profit excluding non-recurring items of 87.614 million CNY, an increase of 126.24% [1] - The debt ratio stood at 30.08%, with investment income of 60.6847 million CNY and financial expenses of -43.8233 million CNY, while the gross profit margin was 47.02% [1]

Market Overview - A-shares experienced a rise and subsequent pullback during the week of October 27 to 31, with the Shanghai Composite Index breaking through 4000 points for the first time in 10 years [1] - By the end of the week, the Shanghai Composite Index increased by 0.11%, the Shenzhen Component Index rose by 0.67%, and the ChiNext Index gained 0.5% [1] Sector Performance - Quantum technology concepts led the gains, while sectors such as new energy, cultivated diamonds, and storage chips also showed active performance [1] - The banking and construction materials sectors attracted significant capital inflows, with banks receiving a net inflow of 8.45 billion yuan [8] Stock Performance - A total of 23 stocks saw a rise of over 30%, with Time Space Technology and Strait Innovation both exceeding 60% gains [4] - Conversely, 80 stocks experienced a decline of over 10%, with eight stocks, including Pearl River Piano and Sino Medical, dropping more than 20% [4] Trading Activity - 49 stocks had a turnover rate exceeding 100%, with Chaoying Electronics leading at 279.46% [6] - The electronics, pharmaceutical, and computer sectors dominated the high turnover stocks [6] Institutional Interest - 425 companies were surveyed by institutions, with Union Medical receiving the most attention from 317 institutions [13] - Institutions focused on sectors such as pharmaceuticals, industrial machinery, electronic components, and electrical equipment [13] Financing Activity - A total of 2032 stocks received net financing purchases, with 170 stocks exceeding 100 million yuan in net purchases [11] - Shenghong Technology topped the list with a net purchase of 18.46 billion yuan [12] New Ratings - 87 stocks received initial attention from institutions, with Naxin Micro receiving a "Buy" rating and a target price of 207 yuan [15][16] - Other stocks such as Tengjing Technology and Kingsoft Office also received favorable ratings from various securities firms [16][17]